Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,125 | 1 | 83.9% |
| Food and Beverage | $219.45 | 3 | 5.9% |
| Travel and Lodging | $205.88 | 1 | 5.5% |
| Education | $175.10 | 6 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,125 | 1 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $238.39 | 2 | $0 (2020) |
| Celgene Corporation | $108.38 | 1 | $0 (2017) |
| Incyte Corporation | $99.00 | 1 | $0 (2017) |
| AbbVie, Inc. | $78.56 | 1 | $0 (2018) |
| PFIZER INC. | $76.10 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $3,125 | 1 | Novartis Pharmaceuticals Corporation ($3,125) |
| 2020 | $238.39 | 2 | Regeneron Pharmaceuticals, Inc. ($238.39) |
| 2019 | $41.85 | 3 | PFIZER INC. ($41.85) |
| 2018 | $112.81 | 3 | AbbVie, Inc. ($78.56) |
| 2017 | $207.38 | 2 | Celgene Corporation ($108.38) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/19/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| 02/19/2020 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $205.88 | General |
| 02/18/2020 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $32.51 | General |
| 04/03/2019 | PFIZER INC. | BESPONSA (Biological) | Education | In-kind items and services | $10.90 | General |
| Category: ONCOLOGY | ||||||
| 02/11/2019 | PFIZER INC. | BESPONSA (Biological) | Education | In-kind items and services | $10.90 | General |
| Category: ONCOLOGY | ||||||
| 01/08/2019 | PFIZER INC. | MYLOTARG (Biological) | Education | In-kind items and services | $20.05 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $78.56 | General |
| Category: Virology | ||||||
| 05/17/2018 | PFIZER INC. | MYLOTARG (Biological) | Education | In-kind items and services | $14.20 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2018 | PFIZER INC. | MYLOTARG (Biological) | Education | In-kind items and services | $20.05 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2017 | Celgene Corporation | CC-486 (Drug) | Food and Beverage | In-kind items and services | $108.38 | General |
| 04/19/2017 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 32 | 73 | $25,374 | $5,759 |
| 2021 | 1 | 13 | 43 | $14,604 | $3,702 |
| 2020 | 1 | 11 | 33 | $10,164 | $2,907 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 49 | $16,758 | $4,157 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 24 | $8,616 | $1,602 | 18.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 43 | $14,604 | $3,702 | 25.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 33 | $10,164 | $2,907 | 28.6% |
About Jonathan Gerber
Jonathan Gerber is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1275679201.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jonathan Gerber has received a total of $3,725 in payments from pharmaceutical and medical device companies, with $3,125 received in 2021. These payments were reported across 11 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($3,125).
As a Medicare-enrolled provider, Gerber has provided services to 56 Medicare beneficiaries, totaling 149 services with total Medicare billing of $12,368. Data is available for 3 years (2020–2022), covering 4 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology
- Location New York, NY
- Active Since 01/29/2007
- Last Updated 03/26/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1275679201
Products in Payments
- CC-486 (Drug) $108.38
- Venclexta (Drug) $78.56
- MYLOTARG (Biological) $54.30
- BESPONSA (Biological) $21.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555